Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Adaptive Biotechnologies Corp (Adaptive Biotechnologies) is a developer of immune-driven medicine. The company's activities carry out decoding and deploying the immune system's capabilities to improve disease diagnosis and treatment. It provides an immune-sequencing platform to laboratories for conducting research in the areas of oncology and other immune-mediated diseases and TCR screening for the development of vaccines. Adaptive Biotechnologies products are utilized by healthcare providers to address various diseases, enhancing patient care across multiple medical fields. The company operates across the US. Adaptive Biotechnologies is headquartered in Seattle, Washington, the US.
Headquarters
United States of America
Address
1165 Eastlake Ave E, Seattle, Washington, 98109
Website
www.adaptivebiotech.com
Telephone
1 206 6590067
No of Employees
624
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ADPT (NASD)
Revenue (2024)
$277.0M
54.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
62.7%
(2024 vs 2023)
Market Cap*
$3.6B
Net Profit Margin (2024)
XYZ
75.9%
(2024 vs 2023)
* As of and is in US$
Adaptive Biotechnologies Corp premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| immunoSEQ | Drug Discovery |
| immunoSEQ T-MAP | Life Sciences Research |
| T-Detect | Biopharma Services |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In July, the company and Flatiron Health entered into a partnership to integrate clonoSEQ test for measurable residual disease (MRD) assessment in lymphoid malignancies into OncoEMR. |
| 2025 | New Products/Services | In April, the company announced that Palmetto GBA, a Medicare Administrative Contractor, expanded coverage of its clonoSEQ assay to include single-time point testing for monitoring recurrence in patients with mantle cell lymphoma. |
| 2025 | New Products/Services | In March, the company introduced an upgraded version of its clonoSEQ assay for measurable residual disease (MRD) detection. |
Competitor Comparison
| Key Parameters | Adaptive Biotechnologies Corp | Illumina Inc | Natera Inc | 10X Genomics Inc | iRepertoire Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Seattle | San Diego | Austin | Pleasanton | Huntsville |
| State/Province | Washington | California | Texas | California | Alabama |
| No. of Employees | 624 | 8,600 | 6,135 | 1,178 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Chad Robins | Chairman; Chief Executive Officer | Executive Board | 2009 | 51 |
| Kyle Piskel | Chief Financial Officer | Senior Management | 2024 | 42 |
| Julie Rubinstein | Chief Operating Officer; President | Senior Management | 2023 | 54 |
| Francis Lo | Chief People Officer | Senior Management | 2019 | 45 |
| Harlan Robins, PhD | Chief Scientific Officer | Senior Management | 2009 | 53 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer